U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C22H22NO4S2.Ca
Molecular Weight 897.167
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZOFENOPRIL CALCIUM

SMILES

[Ca++].C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C([O-])=O)SC3=CC=CC=C3.C[C@H](CSC(=O)C4=CC=CC=C4)C(=O)N5C[C@H](C[C@H]5C([O-])=O)SC6=CC=CC=C6

InChI

InChIKey=NSYUKKYYVFVMST-LETVYOFWSA-L
InChI=1S/2C22H23NO4S2.Ca/c2*1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17;/h2*2-11,15,18-19H,12-14H2,1H3,(H,25,26);/q;;+2/p-2/t2*15-,18+,19+;/m11./s1

HIDE SMILES / InChI

Description

Zofenopril is an inhibitor of Angiotensin Converting Enzyme (ACE), which is approved in Europe for the treatment of hypertension and acute myocardial infarction.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Angiotensin-converting enzyme
97
Target ID: P12821
Gene ID: 1636.0
Gene Symbol: ACE
Target Organism: Homo sapiens (Human)
Inhibitor
8297
 10.9 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
ZOPRANOL

Approved Use

ZOPRANOL is indicated for the treatment of mild to moderate essential hypertension.

Launch Date

2000
Primary
Approved
8429
ZOPRANOL

Approved Use

ZOPRANOL is indicated for the treatment initiated within the first 24 hours of patients with acute myocardial infarction with or without signs and symptoms of heart failure.

Launch Date

2000
PubMed

PubMed

TitleDatePubMed
Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
1989
Zofenopril after anterior myocardial infarction.
1995 Jun 22
Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double-blind, controlled, prospective studies.
2015
Zofenopril Protects Against Myocardial Ischemia-Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability.
2016 Jul 5
Efficacy of Zofenopril Compared With Placebo and Other Angiotensin-converting Enzyme Inhibitors in Patients With Acute Myocardial Infarction and Previous Cardiovascular Risk Factors: A Pooled Individual Data Analysis of 4 Randomized, Double-blind, Controlled, Prospective Studies.
2017 Jan
Patents

Patents

JP2003503381A
35
JP2006513266A
25
JP4729259B2
38
JPH01156913A
3

Sample Use Guides

In Vivo Use Guide
The usual effective dose in hypertension is 30 mg/day (in patients without volume or salt depletion) and the starting dose is 7.5 or 15 mg/day (in patients with volume or salt depletion). In acute myocardial infarction the treatment scheme is the following: 7.5 mg every 12 h (1st and 2nd day); 15 mg every 12 h (3rd and 4th day); 30 mg every 12 h (from 5th day).
Route of Administration: Oral
In Vitro Use Guide
Zofenopril (36 uM) significantly increased coronary flow after 5 min of incubation with isolated rat hearts.
Name Type Language
ZOFENOPRIL CALCIUM
MART.   USAN   WHO-DD  
USAN  
Official Name English
ZOFENOPRIL CALCIUM SALT
MI  
Common Name English
ZOPRACE
Brand Name English
(4S)-N-((S)-3-MERCAPTO-2-METHYLPROPIONYL)-4-(PHENYLTHIO)-R-PROLINE BENZOATE (ESTER), CALCIUM SALT
Common Name English
ZOFENOPRIL CALCIUM [MART.]
Common Name English
ZOFENOPRIL CALCIUM [USAN]
Common Name English
SQ-26991
Code English
SQ 26991
Code English
Zofenopril calcium [WHO-DD]
Common Name English
ZOFENOPRIL CALCIUM SALT [MI]
Common Name English
R-PROLINE, 1-(3-(BENZOYLTHIO)-2-METHYL-1-OXOPROPYL)-4-(PHENYLTHIO)-, CALCIUM SALT, (1(R*),2.ALPHA.,4.ALPHA.)-
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C247
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
Code System Code Type Description
USAN
U-63
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
DRUG BANK
DBSALT002196
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
MERCK INDEX
m11656
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY Merck Index
RXCUI
259493
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY RxNorm
FDA UNII
88ZQ329PU2
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
SMS_ID
100000091302
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
EVMPD
SUB05191MIG
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
PUBCHEM
3033690
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
CHEBI
82600
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
NCI_THESAURUS
C82220
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
CAS
81938-43-4
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
EPA CompTox
DTXSID1048625
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
ChEMBL
CHEMBL331378
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of ZOFENOPRILAT
PARENT (SALT/SOLVATE)
Structure of ZOFENOPRIL
SUBSTANCE RECORD
Structure of ZOFENOPRIL CALCIUM
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966